Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glumetinib in Advanced MET-positive NSCLC
NCT04270591Phase 2Recruiting
- Sponsor
- Haihe
- Start
- Jul 2019
- Primary completion
- Oct 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 2 trial of glumetinib in non-small cell lung cancer (NSCLC), pulmonary sarcomatoid carcinoma (PSC), sponsored by Haihe. Started Jul 2019; status: recruiting.
02
Drugs
glumetinib
03
Conditions
non-small cell lung cancer (NSCLC)pulmonary sarcomatoid carcinoma (PSC)
Beyond the preview
Go deeper on NCT04270591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04270591.